Results 91 to 100 of about 16,802 (177)

Assessment of bone density and microarchitecture in patients with familial partial lipodystrophy. [PDF]

Front Endocrinol (Lausanne)
Muniz RBG, Valerio CM, da Gama EMF, Smith BG, Viola LF, Franco Farias MCPS, Gomes E Silva de Macedo PSM, Moreira RO, Godoy-Matos AF, Farias MLF, Madeira M.   +10 more
europepmc   +1 more source

Descending Lipodystrophy [PDF]

Proceedings of the Royal Society of Medicine, 1927
openaire   +2 more sources

Liver Lipodystrophy in Barraquer-Simons Syndrome: How Much Should We Worry About? [PDF]

Life (Basel)
Georgescu D, Lighezan DF, Buzas R, Ciubotaru PG, Țunea OE, Suceava I, Albu TA, Jurescu A, Ioniță M, Reisz D.   +9 more
europepmc   +1 more source

Postmarketing Surveillance of the Safety and Effectiveness of Metreleptin in Patients with Lipodystrophy in Japan. [PDF]

J Endocr Soc
Ebihara K, Hata T, Sato Y, Miyano M.
europepmc   +1 more source

Progressive Lipodystrophy

Journal of British Surgery, 1966
openaire   +2 more sources

Impact of Juvenile Dermatomyositis on Growth, Puberty, Bone Mineral Density, and Body Composition in Children. [PDF]

Mediterr J Rheumatol
Sudhera N, Kaur H, Pandiarajan V, Singh S.   +3 more
europepmc   +1 more source

Leptin Therapy Improves Metabolic Dysfunction in Immune Checkpoint Inhibitor-induced Lipodystrophy. [PDF]

JCEM Case Rep
Vahidi Rad M, Saad-Omer S, Suresh Kumar Bindu BN, Simha V.   +3 more
europepmc   +1 more source

Variable Expressivity in Type 2 Familial Partial Lipodystrophy Related to a Pathogenic <i>LMNA</i> Variant R482: Maternal Transmission to Non-Identical Twins. [PDF]

Appl Clin Genet
Duque-Cordoba PA, Diaz-Ordoñez L, Carvajal-Del-Castillo L, Marmolejo D, Leal AF, Pachajoa H.   +5 more
europepmc   +1 more source

Case Report: Generalized lipodystrophy following immune-checkpoint inhibitor therapy. [PDF]

Front Endocrinol (Lausanne)
Lee AH, Hui R, Gunton JE.
europepmc   +1 more source

Lipodystrophy [PDF]

, 2020
openaire   +1 more source